Funding for this research was provided by:
Japan Agency for Medical Research and Development (JP21fk0210058, JP21fk0210065, JP21fk0210073, JP21fk0210090)
Received: 15 June 2021
Accepted: 8 November 2021
First Online: 19 November 2021
: The study protocol was approved by the Human Ethics Review Committee at Toranomon Hospital and each patient provided a signed informed consent at the time of liver histological diagnosis. The study was conducted in compliance with the International Conference on Harmonization guidelines for Good Clinical Practice (E6) and the 2013 Declaration of Helsinki.
: Not applicable.
: (1) Hiromitsu Kumada has received honoraria from Gilead Sciences, AbbVie Inc., Eisai Co., Ltd, and Dainippon Sumitomo Pharma. (2) Yusuke Kawamura has received honoraria from Eisai Co., Ltd. All other authors declare no conflict of interest.
: This paper has not been published or presented elsewhere in part or in entirety, and is not under consideration by another journal.